Photo from wikipedia
Tildrakizumab (Ilumetri) is a new biological therapy targeting interleukin (IL)‐23 for the treatment of plaque psoriasis in adults. This article discusses its place in therapy and clinical trial efficacy. Click to show full abstract
Tildrakizumab (Ilumetri) is a new biological therapy targeting interleukin (IL)‐23 for the treatment of plaque psoriasis in adults. This article discusses its place in therapy and clinical trial efficacy.
Keywords:
plaque psoriasis;
psoriasis adults;
treatment plaque
Journal Title: Prescriber
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!